Project Grant R01CA288760
Award Date 8/1/25
Completion Date 7/31/30
Dollars Obligated $355K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Maryland, USA
Similar Awards
- This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) to Emory University provides $659,498.00 to conduct research on racial disparities in the mechanisms of prostate cancer metastasis. The project aims to analyze differential pathway activity, particularly involving the FGFR3 signaling and oxidative phosphorylation (OXPHOS) pathways, and their impact on metastasis in African American prostate cancer patients. The research will utilize in vitro and...
- This Project Grant award from the National Cancer Institute (NCI), under the Cancer Cause and Prevention Research program (CFDA 93.393), will support research conducted by Thomas Jefferson University to investigate genomic factors contributing to racial disparities in metastatic prostate cancer outcomes. The key products or services to be delivered under this $156,000 award include whole-exome sequencing of circulating tumor cells (CTCs) from paired Black and White patients with metastatic...
- This $663,383 Project Grant was awarded by the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) to Georgetown University on August 1, 2025. The project aims to conduct proactive outreach and provide streamlined genetic testing for prostate cancer survivors. This research is crucial to customize cancer treatment and guide prevention, as germline pathogenic variants in DNA-repair genes are common and clinically significant in prostate cancer patients. Despite clear...
- This Project Grant award, valued at $531,825.00 and funded by the National Cancer Institute (CFDA 93.396 - Cancer Biology Research), supports research by The Trustees of Columbia University in the City of New York to uncover the molecular mechanisms underlying castration sensitivity in the prostate epithelium. The research aims to define the intrinsic and extrinsic pathways that mediate castration response and ferroptosis, a form of regulated cell death, in the normal prostate. This work may...
- The University of Southern California was awarded a $613,220 Project Grant under the National Cancer Institute's Cancer Cause and Prevention Research (CFDA 93.393) program. The grant, which runs from February 1, 2025 to January 31, 2030, will fund research to investigate the contribution of germline copy number variations to the susceptibility of aggressive prostate cancer in men of African and European ancestry. The project aims to leverage existing genome-wide association study, whole-exome...
- The University of Pennsylvania received a $371,719 Project Grant award from the National Cancer Institute (CFDA 93.393 Cancer Cause and Prevention Research program) to conduct research towards characterizing epigenetic targets in prostate cancer. The 5-year project, awarded on March 1, 2025, aims to identify, characterize, and therapeutically target co-factors and chromatin-associated proteins involved in the androgen receptor signaling pathway in prostate cancer. Specifically, the research will...
- This Project Grant award of $109,076 from the National Cancer Institute's Cancer Research Manpower program (CFDA 93.398) supports research to identify patterns of gene deletions in metastatic breast cancer. The award, which runs from January 21, 2026 to July 31, 2029, aims to leverage machine learning techniques and comprehensive autopsy data to create a detailed landscape of genomic evolution in late-stage metastatic disease. The research, conducted by the University of Pittsburgh, seeks to...
- The U.S. National Cancer Institute (NCI) awarded a 5-year, $680,433 Project Grant to the University of California, San Francisco (UCSF) under the NCI's Cancer Detection and Diagnosis Research (CFDA 93.394) program. The grant supports research aimed at using cutting-edge spatial proteogenomic technologies and pathology artificial intelligence (PAI) to improve prognostic estimation and elucidate the underlying biology driving PAI outcomes in prostate cancer. The project seeks to: 1) understand the...
- This Project Grant award, valued at $129,058.00 and provided by the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower), supports research by Dr. Anqi Wang at the University of Southern California to investigate the role of loss of Y chromosome (LOY) across the prostate cancer continuum. The research aims to evaluate LOY as a potential biomarker for prostate cancer etiology, detection, treatment, and prognosis, leveraging large prospective cohorts. The project will involve...
- This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) will support research at the Weill Medical College of Cornell University to investigate the role of early oncogenic drivers in maintaining lineage fidelity in prostate cancer. The $683,979 award, effective June 1, 2025 through April 30, 2030, will fund a multi-institutional collaborative effort to define the propensity of prostate cancers harboring SPOP mutations to progress to specific subtypes...